{"transactions":[{"id":3885570,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":165546,"kind":"person","name":"LOAR MATTHEW M","position":1,"cik":"0001236260","reported_name":"LOAR MATTHEW M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2018-06-22T20:12:51.000Z","date":"2018-06-20","kind":"grant","acquired":true,"shares":500000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Mr. Loar was awarded options to purchase Mateon Therapeutics, Inc. common stock, $0.01 par value per share (the \"2015 Plan Options\" and, collectively with the 2017 Plan Options, the \"Options\"), pursuant to the Amended and Restated Mateon Therapeutics, Inc. 2015 Equity Incentive Plan in connection with his service as Chief Financial Officer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Options will vest in twelve equal monthly installments beginning one month after the date of grant."}],"balance_after":500000,"derivative":{"exercise_price":0.22,"expiration_date":"2028-06-20","underlying":"Common Stock","underlying_shares":500000},"source":{"system":"sec-edgar","filing":"0001209191-18-039169","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/908259/000120919118039169/doc4.xml","form_type":"4"}},{"id":3885569,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":165546,"kind":"person","name":"LOAR MATTHEW M","position":1,"cik":"0001236260","reported_name":"LOAR MATTHEW M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2018-06-22T20:12:51.000Z","date":"2018-06-20","kind":"grant","acquired":true,"shares":250000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Mr. Loar was awarded options to purchase Mateon Therapeutics, Inc. common stock, $0.01 par value per share (the \"2017 Plan Options\"), pursuant to the Mateon Therapeutics, Inc. 2017 Equity Incentive Plan in connection with his service as Chief Financial Officer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Options will vest in twelve equal monthly installments beginning one month after the date of grant."}],"balance_after":250000,"derivative":{"exercise_price":0.22,"expiration_date":"2028-06-20","underlying":"Common Stock","underlying_shares":250000},"source":{"system":"sec-edgar","filing":"0001209191-18-039169","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/908259/000120919118039169/doc4.xml","form_type":"4"}},{"id":3963499,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":165546,"kind":"person","name":"LOAR MATTHEW M","position":1,"cik":"0001236260","reported_name":"LOAR MATTHEW M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock B Warrant (Right to Buy)","published_at":"2018-04-16T20:22:00.000Z","date":"2018-04-12","kind":"purchase","acquired":true,"shares":125000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities are included within one Unit purchased by the reporting person for $50,000 per Unit pursuant to a Subscription Agreement between the reporting person and Mateon Therapeutics, Inc. (the \"Company\"), dated April 12, 2018 (the \"Subscription Agreement\"). Each Unit consists of (i) 250,000 shares of Common Stock of the Company, par value $0.01 per share (the \"Common Stock\"), (ii) an \"A\" warrant to purchase 125,000 shares of Common Stock at an exercise price of $0.40 per share and (iii) a \"B\" warrant to purchase 125,000 shares of Common Stock at an exercise price of $0.40 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Common Stock B Warrants shall become exercisable immediately following the Company's stockholders' approval of an increase in the number of the Company's authorized shares of Common Stock sufficient to cover the number of shares issuable upon the exercise of all of the Common Stock B Warrants (the \"Stock Authorization\"). The Company is obligated to effect the Stock Authorization no later than June 30, 2018 (the \"Authorization Date\")."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Common Stock B Warrants shall expire on the date that is two years after the Stock Authorization is effected (the \"Expiration Date\"). In the event that the Company fails to effect the Stock Authorization by the Authorization Date, the Expiration Date will be extended for two additional years."}],"balance_after":125000,"derivative":{"exercise_price":0.4,"underlying":"Common Stock","underlying_shares":125000},"source":{"system":"sec-edgar","filing":"0001209191-18-024986","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/908259/000120919118024986/doc4.xml","form_type":"4"}},{"id":3963498,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":165546,"kind":"person","name":"LOAR MATTHEW M","position":1,"cik":"0001236260","reported_name":"LOAR MATTHEW M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock A Warrant (Right to Buy)","published_at":"2018-04-16T20:22:00.000Z","date":"2018-04-12","kind":"purchase","acquired":true,"shares":125000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities are included within one Unit purchased by the reporting person for $50,000 per Unit pursuant to a Subscription Agreement between the reporting person and Mateon Therapeutics, Inc. (the \"Company\"), dated April 12, 2018 (the \"Subscription Agreement\"). Each Unit consists of (i) 250,000 shares of Common Stock of the Company, par value $0.01 per share (the \"Common Stock\"), (ii) an \"A\" warrant to purchase 125,000 shares of Common Stock at an exercise price of $0.40 per share and (iii) a \"B\" warrant to purchase 125,000 shares of Common Stock at an exercise price of $0.40 per share."}],"balance_after":125000,"derivative":{"exercise_price":0.4,"exercise_date":"2018-04-12","expiration_date":"2020-04-12","underlying":"Common Stock","underlying_shares":125000},"source":{"system":"sec-edgar","filing":"0001209191-18-024986","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/908259/000120919118024986/doc4.xml","form_type":"4"}},{"id":3963497,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":165546,"kind":"person","name":"LOAR MATTHEW M","position":1,"cik":"0001236260","reported_name":"LOAR MATTHEW M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2018-04-16T20:22:00.000Z","date":"2018-04-12","kind":"purchase","acquired":true,"shares":250000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities are included within one Unit purchased by the reporting person for $50,000 per Unit pursuant to a Subscription Agreement between the reporting person and Mateon Therapeutics, Inc. (the \"Company\"), dated April 12, 2018 (the \"Subscription Agreement\"). Each Unit consists of (i) 250,000 shares of Common Stock of the Company, par value $0.01 per share (the \"Common Stock\"), (ii) an \"A\" warrant to purchase 125,000 shares of Common Stock at an exercise price of $0.40 per share and (iii) a \"B\" warrant to purchase 125,000 shares of Common Stock at an exercise price of $0.40 per share."}],"balance_after":300000,"source":{"system":"sec-edgar","filing":"0001209191-18-024986","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/908259/000120919118024986/doc4.xml","form_type":"4"}},{"id":4491432,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":165546,"kind":"person","name":"LOAR MATTHEW M","position":1,"cik":"0001236260","reported_name":"LOAR MATTHEW M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2017-01-13T22:01:58.000Z","date":"2017-01-12","kind":"grant","acquired":true,"shares":350000,"price":0.375,"value":131250.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Mr. Loar was awarded options to purchase shares of Mateon Therapeutics, Inc. common stock, $0.01 par value per share, pursuant to the Mateon Therapeutics, Inc. 2017 Equity Incentive Plan in connection with his service as Chief Financial Officer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Options will vest in forty-eight equal monthly installments beginning one month after the grant date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Mr. Loar was awarded options to purchase shares of Mateon Therapeutics, Inc. common stock, $0.01 par value per share, pursuant to the Mateon Therapeutics, Inc. 2017 Equity Incentive Plan in connection with his service as Chief Financial Officer."}],"balance_after":350000,"derivative":{"exercise_price":0.375,"expiration_date":"2027-01-12","underlying":"Common Stock","underlying_shares":350000},"source":{"system":"sec-edgar","filing":"0001209191-17-003702","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/908259/000120919117003702/doc4.xml","form_type":"4"}}]}